EGFR and glioblastoma: The analysis yielded a pooled HR of 0.94 (95% CI: 0.78–1.13, p = 0.49), indicating that the co-occurrence of EGFR amplification and the EGFRvIII mutation is not significantly associated with poorer overall survival in GBM patients (Figure 4a).